EQS-News: Epigenomics AG / Key word(s): PersonnelEpigenomics AG: Resignation of Supervisory Board Chairman Heino von Prondzynski 27.01.2023 / 18:08 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics AG: Resignation of Supervisory Board Chairman Heino von Prondzynski Berlin (Germany), January 27, 2023 -The Chairman of the Supervisory Board of Epigenomics AG (Frankfurt […]
Category: Press Releases
27. January 2023
Epigenomics AG: Resignation of Supervisory Board Chairman Heino von Prondzynski
23. December 2022
Pareto Securities AS publishes buy recommendation for Epigenomics AG share
EQS-News: Epigenomics AG / Key word(s): Research Update/Study resultsPareto Securities AS publishes buy recommendation for Epigenomics AG share 23.12.2022 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Pareto Securities AS publishes buy recommendation for Epigenomics AG share Berlin (Germany), December 23, 2022 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: […]
14. December 2022
Epigenomics Releases Performance Data on Next Generation Test
EQS-News: Epigenomics AG / Key word(s): Study results/MiscellaneousEpigenomics Releases Performance Data on Next Generation Test 14.12.2022 / 05:23 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics Releases Performance Data on Next Generation Test Epigenomics’ Next Generation test demonstrates 84% sensitivity in pre-clinical testing. Performance exceeds on-market standard of FIT testing for […]
14. December 2022
Epigenomics Licenses Protein Biomarker Technology for Blood-based Colorectal Cancer Test
EQS-News: Epigenomics AG / Key word(s): Alliance/MiscellaneousEpigenomics Licenses Protein Biomarker Technology for Blood-based Colorectal Cancer Test 14.12.2022 / 05:16 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics Licenses Protein Biomarker Technology for Blood-based Colorectal Cancer Test Combined technologies have the potential to create a high-performance, cost-effective, blood-based CRC testing solution Berlin […]
09. November 2022
Epigenomics AG reports financial results for the first nine months 2022
EQS-News: Epigenomics AG / Key word(s): 9 Month figures/Quarter ResultsEpigenomics AG reports financial results for the first nine months 2022 09.11.2022 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics AG reports financial results for the first nine months 2022 Berlin (Germany) and San Diego, CA (U.S.A.), November 9, […]
19. September 2022
Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test
EQS-News: Epigenomics AG / Key word(s): StudyEpigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test 19.09.2022 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test First subject has been enrolled in the Company’s CRC-DRAW trial Data […]